版本:
中国

BRIEF-PhaseRx reports Q4 loss per share of $0.30

March 27 Phaserx Inc

* PhaseRx reports fourth quarter and full year 2016 financial results and provides corporate update

* Q4 loss per share $0.30

* As of December 31, 2016, company had cash, cash equivalents, and marketable securities of $15.5 million

* Believes it has sufficient cash to fund its operations for at least next 12 months

* In 2017, anticipate completing GLP toxicology and GMP manufacturing activities and submitting an ind for PRX-OTC in Q4 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐